|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ANZCTR |
|
Last refreshed on:
|
13 January 2020 |
|
Main ID: |
ACTRN12611000994987 |
|
Date of registration:
|
19/09/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effect of Mupirocin in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial
|
|
Scientific title:
|
Effect of Mupirocin on S.aureus infection in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial |
|
Date of first enrolment:
|
18/01/2010 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://anzctr.org.au/ACTRN12611000994987.aspx |
|
Study type:
|
Interventional |
|
Study design:
|
Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;
|
|
Phase:
|
Phase 2 / Phase 3
|
|
|
Countries of recruitment
|
|
Australia
| | | | | | | |
|
Contacts
|
|
Name:
|
Josh Jervis-Bardy
|
|
Address:
|
Department of Otolaryngology Head & Neck Surgery
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
South Australia 5011
Australia |
|
Telephone:
|
+61 8 82226000 |
|
Email:
|
josh.bardy@hotmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Josh Jervis-Bardy
|
|
Address:
|
Department of Otolaryngology Head & Neck Surgery
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
South Australia 5011
Australia |
|
Telephone:
|
+61 8 82226000 |
|
Email:
|
josh.bardy@hotmail.com |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Patients with surgically-recalcitrant, S.aureus-positive chronic rhinosinusitis
Exclusion criteria: Mupirocin allergy.
Augmentin Duo allergy.
Multiple bacterial species on culture.
MRSA.
Mupirocin-resistant S.aureus.
Age minimum:
18 Years
Age maximum:
No limit
Gender:
Both males and females
|
|
Health Condition(s) or Problem(s) studied
|
Chronic Rhinosinusitis;
Chronic Rhinosinusitis
|
|
Infection - Studies of infection and infectious agents
|
|
Intervention(s)
|
|
Mupirocin nasal rinses, 0.05% twice daily for 4 weeks.
|
|
Primary Outcome(s)
|
|
S.aureus infection, as assessed by endoscopically-guided nasal swab[At end of 4-week treatment]
|
|
Secondary Outcome(s)
|
|
Signs and symptoms of chronic rhinosinusitis, as assessed by the sinonasal outcome test (SNOT-20) and the Lund-Kennedy endoscopic examination score.[At end of 4-week treatment]
|
|
Source(s) of Monetary Support
|
|
Department of Otolaryngology Head & Neck Surgery
|
|
Ethics review
|
Status: Approved
Approval date:
Contact:
Ethics of Human Research Committe (TQEH & LMH)
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|